|Day Low/High||55.43 / 58.62|
|52 Wk Low/High||45.50 / 85.00|
Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.
Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Tibco Software, Arena Pharma, and Church & Dwight.
If a stock is up 500% in a straight line, you take something off the table.
Despite some worrisome action, the uptrend is still intact. Keep an eye on this particular level.
Senior columnist Adam Feuerstein says Arena Pharmaceuticals is the next big thing in biotech.
The company wants to create a specialty finance business that will provide capital to help fund testing for drugs or devices.
In this trend I look for momentum, velocity, acceleration and speed, especially with options.
Adam Feuerstein, senior columnist for TheStreet, says Arena Pharmaceuticals is the next big thing in biotech.
Portfolio Manager David Peltier recaps the highlights of his monthly live Twitter chat.
Portfolio manager David Peltier discusses where he's putting money to work during the market correction.
While the bank's loss is embarrassing, this could also be a buying opportunity
Jim Cramer explains it's important for smaller companies to have the opportunity to come up with solutions to dreaded diseases like obesity.
Portfolio Manager David Peltier @davidspeltier recaps his latest live #SU10chat on Twitter.